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Nitric oxide (NO) is primarily a modulator of vascular tone and has many features of an ideal 
pulmonary vasodilator. When inhaled, it has a rapid onset of action, is delivered directly to 
the lungs thereby minimizing systemic side effects, and improves ventilation-perfusion 
mismatch. (1) 
Inhaled Nitric Oxide (iNO) was first approved by the Food and Drug Administration in 1999 
for use in neonates with Persistent Pulmonary Hypertension of the Newborn (PPHN). Since 
then there has been considerable interest in its possible role as a pulmonary vasodilator in 
other conditions. (2) 
Although it has been validated for use in PPHN by numerous randomised controlled trials 
(RCTs), its use in other settings is not widely supported. (2, 3) Whilst there is often an 
improvement in oxygenation observed with its use, it is not known if this translates into an 
improvement in morbidity and mortality, or whether there are subgroups of patients that 
respond preferentially to treatment. In our resource limited setting, it is often employed in 
severe, refractory hypoxaemia secondary to acute respiratory distress syndrome (ARDS) and 
in pulmonary hypertension (PHT) following cardiac surgery. It is an expensive treatment that 
is used without a protocol to guide its use and weaning, and this is often left to the discretion 
of the attending physician.  
 
NO is synthesized from the terminal nitrogen of L-arginine by the enzyme nitric oxide 
synthase (NOS) in vascular endothelial cells. NO then diffuses into vascular smooth muscle 
where it binds to soluble guanylate cyclase to convert guanosine triphosphate into cyclic 
guanosine monophosphate (CGMP). CGMP then mediates vascular smooth muscle 
relaxation thereby improving perfusion and in turn, oxygenation. Ventilation-perfusion 
mismatch is improved as iNO is preferentially delivered to well aerated lung segments. (1) 
Decreased pulmonary vascular pressures may also reduce right to left intra-cardiac shunting 
through a patent ductus arteriosus or patent foramen ovale if present.  
Once in the bloodstream, iNO binds with iron in oxyhaemoglobin to form methaemoglobin 
and nitrate, and with deoxyhaemoglobin to form iron-nitrosyl-globin. It is rapidly inactivated 
which largely accounts for its low side effect profile. (3, 4) 
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Inhalation of low levels of NO appears to be safe. The major clinical toxic effects are due to 
the formation of nitrogen dioxide which may cause pulmonary oedema and 
methaemoglobinaemia which may result in hypoxia. These are however usually observed 
when high doses of iNO, usually more than 80ppm, are used. It is recommended that serum 
methaemoglobin be measured at 8hours and 24hours, and treatment weaned or discontinued 
if levels methaemoglobin levels rise above 5%. Other adverse effects may include bleeding 
due to impaired platelet adhesion and aggregation and renal dysfunction, although these are 
not usually observed in the paediatric population. iNO mediated lung injury may occur and 
results primarily from inactivation of surfactant protein A and decreased surfactant 
production. Prolonged iNO exposure is associated with a transient increase in markers of 
oxidative lung injury. (5) 
  
In vitro, nitric oxide has been shown to have some bacteriostatic effect and some immune 
modulatory effects. This has however not been proven in vivo. (6, 7) Leukocyte activation is 
inhibited thereby inhibiting the generation of oxygen free radicals. (2, 8) In addition, immune 
function is affected by modified cytokine release from alveolar macrophages, and inhibition 
of active adhesion molecules and inhibition of the neutrophil oxidative burst involved in 
neutrophil migration. Attenuation of the inflammatory response, particularly in lung injury 
associated with sepsis, may therefore be an important factor in the success or failure of 
treatment with iNO. (9) 
 
There is a lack of standardised guidelines for the dosage and weaning of iNO. A response to 
treatment is usually observed at doses of 20ppm. When iNO is stopped abruptly, rebound 
pulmonary hypertension sometimes develops. This can usually be averted by a slow weaning 
of iNO to 1ppm before discontinuation, increasing FiO2 during weaning, or the concomitant 
use of phosphodiesterase inhibitors. (5) Sildenafil is recommended by the American Heart 
Association to prevent rebound pulmonary hypertension in patients who have evidence of a 
sustained increase in pulmonary artery pressure on withdrawal of iNO or require retreatment 
with iNO despite gradually weaning the dosage. (10) This rebound phenomenon is not seen 
when treatment with iNO is limited to 30 minutes, and for this reason,  treatment should be 








The objective of this literature review is to appraise the outcomes of patients treated with iNO 
for ARDS and pulmonary hypertension following cardiac surgery. Primary outcomes looked 
at will be response to treatment with improved oxygenation, haemodynamics and mortality. 
Secondarily we will try to ascertain whether there are subgroups of patients that respond 
preferentially to treatment. The aim is to gauge whether continued use of this expensive 
treatment modality without strict guidelines is in fact justified in our clinical setting.  
 
Search strategy 
Table 1. Literature Review Search Parameters 
 
An electronic search of the Pubmed and Cocharane databases was undertaken in 2015 and 
again in December 2018. Medical Subject Headings (MeSH) were used in these searches. 
These headings included “Nitric oxide”, “Adult Respiratory Distress Syndrome”, “Pulmonary 
Hypertension” and “Cardiac Surgical Procedures”. Filters were applied to include only 
studies in humans, studies in children, and studies published after 1998, although key RCTs 














































Results were screened based on relevance of the title and review of the abstract. All 
systematic reviews, meta-analyses, randomized controlled trials and recent large retrospective 
studies were included. References in meta-analyses were hand searched as some trials were 
published prior to the time frame used in this search. Studies comparing iNO to other 
therapies or to adjunctive maneuvers, those looking at dose response relationships, use in 
specific cardiac procedures, use in neonates, different methods of delivery and effects on long 




iNO in ARDS 
 
Definitions and practice:  
 
Paediatric ARDS is defined by the presence of respiratory distress, hypoxaemia and bilateral 
infiltrates on chest radiograph. (11) Stricter definitions have been applied for research 
purposes, however, in our setting any lung disease with hypoxaemia is commonly labelled 
ARDS, without differentiation based on underlying cause.  
ARDS may be caused by a number of underlying conditions, and because of this, response to 
treatment may vary. In the literature, patients with ARDS are often analysed as a cohort 
irrespective of underlying cause. Given the heterogeneity in underlying pathology, it is not 
known whether there are subsets of patients with specific conditions that respond 
preferentially to treatment with iNO. (8)  
 
In our unit iNO is administered to patients with refractory hypoxaemia on mechanical 
ventilation via a continuous delivery method, and not non invasively via face mask or 
Continuous Positive Airway Pressure (CPAP) as practiced elsewhere. In patients with ARDS, 
treatment is often initiated based on a clinical suspicion of PHT without echocardiographic 
confirmation, which is largely due to an overburdened cardiology service and difficulty in 
accessing routine echocardiography.  
 A response to treatment is subjectively determined by the attending physician, usually based 
on an improvement in oxygen saturation alone. In the literature, the standard for assessing 
response to treatment in most trials is an improvement in the oxygenation index (OI) of 20 
percent from baseline (8) or an improvement in the ration of PaO2/FiO2 of more than 10 (12, 
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13). The OI is calculated by the formula (FiO2*Mean Airway Pressure)/PaO2. An 
assessment of clinical response based on oxygen saturation alone may be confounded by 
factors such as ventilator settings, adjunctive measures such as prone positioning, sodium 
bicarbonate or neuromuscular blockade.  
The timing of initiation of treatment may also play a role as it is hypothesized that early 
initiation of treatment is associated with improved outcomes. (12) 
Ventilation strategies in our unit are clinician driven rather than protocol driven and are 
guided by arterial blood gas measurements and pulse oximetry. In some studies, protocols 
including the use of regular 6 hourly radiographs are used to guide ventilation which may 
account for a slight variation between findings in the literature and findings in clinical 
practice. (12, 14) 
 
Improvement in Oxygenation: 
 
A systematic review by Afshari et al in 2011 that included 3 paediatric trials (Day, Dobyns, 
Ibrahim) showed that iNO effected only a transient improvement in oxygenation that did not 
extend beyond 24 hours. Dosing regimens however varied in the included trials and it is not 
known whether prolonged fixed dosing may result in tolerance which may have affected 
results. Furthermore, many trials were conducted more than 15 years ago and ventilation 
strategies have advanced since then with a greater focus being placed on lung protective 
ventilatory strategies. (15) An earlier systematic review by Adhikari et al in 2007 including 
two pediatric trials, (11) as well as the European Consensus Statement on the use of iNO in 
Neonates and Children concur that iNO provides only a short, non-sustained improvement in 
oxygenation. (16) 
 
A small RCT by Day et al in 1997 looked at 12 patients treated with iNO and 12 controls. 
Patients were either treated with iNO at 10ppm for 24 hours or conventional treatment, after 
which the control group as well as the initial treatment group were treated with iNO for a 
further 24 hours. They found that whilst the OI in the initial treatment group was improved in 
the first hour following treatment, this was not maintained at 24 hours. Patients in the initial 
control group interestingly demonstrated a sustained improvement in oxygenation beyond 





A large multicenter RCT by Dobyns et al in 1999 assessed response to treatment with 
improved oxygenation. One hundred and eight patients with acute hypoxic respiratory failure 
were enrolled. Treatment with iNO was compared to conventional ventilation alone for 
72hours. Crossover was allowed if patients failed to improve with mechanical ventilation 
alone. Although standardized ventilation protocols were used, the use of HFOV, 
neuromuscular blockade and prone positioning were not stratified for. It was found that at 12 
hours there was a significant improvement in oxygenation in the treatment group, but this 
was not sustained beyond that. (18) 
 
A recent prospective multicenter RCT performed in 2015 by Bronicki et al, including 24 
patients treated with iNO and 29 controls, showed a significant improvement in OI at 12 
hours in the treatment group that was again not sustained beyond 24 hours. (14) 
 
Medjo et al in 2004 prospectively enrolled a treatment group of 16 patients and looked at a 
retrospective group of patients with ARDS that were treated with iNO. They found only a 
short term improvement in oxygenation that was not sustained beyond 24 hours. (13) 
 
Fioretto et al in 2004 showed in a prospectively enrolled treatment group of 18 patients 
compared with a retrospective control group of 21 patients that early initiation of iNO within 
1.5 hours of diagnosis of ARDS, irrespective of the severity of the clinical presentation at the 
time, resulted in an early and sustained improvement in oxygenation. This suggests that the 




A Cochrane review of the literature, including pooled data from 4 paediatric trials, showed no 
improvement in mortality following treatment with iNO in paediatric patients with ARDS. 
The combined number of paediatric patients included in the review were too few to 
demonstrate any other benefits or harm in paediatric patients. (1) 
 
Afshari et al reviewed 3 paediatric RCTs, only one of which did not allow for crossover and 




A review by Adhikari et al found a possible trend towards increased mortality, however this 
was based on trials in adults as the paediatric trials in this review both allowed crossover and 
could not provide information on mortality as an outcome. (11) 
 
The European consensus statement on the use of iNO in ARDS states that iNO has not been 
shown to improve mortality and that further studies that stratify for underlying disease are 
needed. (16) 
 
In a large retrospective study that included 160 patients treated at the Children’s Hospital of 
Philadelphia, Dowell et al in 2017 looked at mortality by stratifying patients according to 
responders to iNO (those with an improvement in oxygenation index or an improvement in 
oxygenation saturation of >20%) and non-responders. No statistical difference in mortality 
was found between the two groups. (8) 
 
Gupta et al in 2016 conducted a large multicenter retrospective study including 521 
propensity score matched paediatric patients from 9 different centres across the United States. 
Patients were enrolled prospectively from an online critical care network that contained 
patient demographics, clinical information and costs of treatments. They also found no 
benefit in mortality. (19)  
 





Dowell et al showed that patients with ARDS that responded to treatment with iNO were less 
likely to require HFOV and ECMO and that there was a significant decrease in ventilator 
days in responders. A standardized protocol for ventilation and the use of iNO was not used 
in this study and a non-invasive method of delivery of iNO was used. This meant that patients 
could be weaned off ventilation irrespective of a continued need for treatment with iNO. The 
authors suggest a trial of iNO in these patients due to the potential for decreased morbidity 
and costs from ECMO, HFOV and ventilator days. This is not relevant in our setting, firstly 
because ECMO was not available in our unit during the time period investigated and 
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secondly because iNO is usually used in patients with ARDS that are already failing 
treatment with HFOV. (8) 
 
Bronicki et al also found that ventilator free days and ECMO free days were higher in the 
group treated with iNO. (14)  
 
Fioretto et al found no appreciable difference in duration of mechanical ventilation and length 
of stay in ICU between treatment groups with early initiation of iNO and control groups. (12) 
 
Medjo et al also reported a decrease in ventilator settings with the use of iNO which might 
result in fewer ventilator-associated complications. (13) 
 
Gupta et al 2016 found significantly worse outcomes in terms of ventilator free days,  
mechanical ventilation and duration of hospital and ICU stay in treatment groups. They also 
showed an increase in costs in patients treated with iNO compared to control groups. This is 
the first study to show increased morbidity and higher costs in patients treated with iNO for 
ARDS. Possible factors contributing to these findings are a detrimental effect of 
discontinuing iNO because of the suppression of endogenous NO production, and longer 
duration of ventilation due to slow weaning of iNO. (19) 
 
Dobyns et al found that patients with severe lung disease and high OI at initiation of 
treatment, as well as patients that were immunocompromised, showed a better response to 
treatment. (18) Dowel et al found that no other demographic or severity of illness variables 
were predictive of an improved response to iNO. (8) 
 
iNO in PHT post cardiac surgery 
 
Definitions and practice: 
 
In the paediatric population PHT is defined as a pulmonary arterial pressure (PAP) 
>25mmHG or PAP greater than 50% of systemic arterial pressures. Acute pulmonary 
hypertensive crises (PHTCs) are defined as an acute increase in PAP with a resultant 
impairment of haemodynamics and oxygenation. The increase in pulmonary vascular 
resistance results in increased right ventricular afterload and eventually impaired cardiac 
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output. (20) It is theorized that the ability of the right ventricle to adapt to an increase in 
afterload rather than the absolute increase in PAP that determines the outcome in pulmonary 
hypertensive crises. (10)  
PHTCs are a major contributor to morbidity and mortality post cardiac surgery. Life 
threatening pulmonary crises are experienced in 7% of these patients and is associated with a 
29% mortality rate. (3) PHTCs may be triggered by pain, hypoxia and suctioning in the post-
operative period.  
The post-operative period, particularly if cardiopulmonary bypass was used, is associated 
with high pulmonary pressures secondary to hypoxia, an excess production of endothelin and 
thromboxane, an increased production of microemboli and ischaemia-reperfusion injury. In 
addition, endogenous production of nitric oxide is decreased in the immediate post operative 
period. (21)  
INO is used in this setting for its desirable effect in improving oxygenation without 
impairment of systemic haemodynamics.  
 
Impact on number of PHT crises: 
 
A Cochrane review that was updated in 2014 including combined data from 4 RCTs (Day, 
Miller, Morris, Russel) and 210 patients found no difference in the number of pulmonary 
hypertensive crises  in patients treated with iNO when compared to controls. The timing of 
initiation of treatment in these trials were however predetermined and treatment was 
administered prophylactically. Russel and Miller commenced treatment immediately post-
operatively, Day, on arrival in ICU, and Morris at a median of 8.5 hours. Dosing also varied 
across trials ranging from 5-40ppm. (3) 
 
A RCT by Day et al, 2000 assessing the impact of iNO on the number of PHTC post-
operatively in 38 patients, showed no statistical difference in the number of PHTCs. Patients 
were recruited if their post-operative pulmonary pressures were more than 50% of systemic 
on cardiac catheterization, and the use of iNO was compared to conventional treatment which 
was determined by the attending physician and was not standardized between groups. (22) 
 
A large RCT by Miller et al in 2000 enrolled 124 infants with preoperative PAP >50% of 
systemic and compared the number of post-operative PHTCs in patients treated with iNO 
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compared to placebo. This trial used continuous prophylactic iNO at a dose of 20ppm. They 
found a 30% reduction in the number of PHTCs in the treatment group. (6)  
 
The American Heart Association recommends that iNO be used as the initial therapy for 
PHTCs and right heart failure following cardiac surgery and that sildenafil be utilized when 
withdrawing iNO, Class 1, Level of Evidence B (i.e. treatment recommended but based on 
single RCT or non-randomized trials). (10) 
 
The European Consensus Statement on the management of pulmonary hypertension in the 
ICU suggests considering the early use of INO following bypass surgery for its benefit in 
reducing pulmonary vascular resistance and its possible role in reducing the number of 
pulmonary hypertensive crises and shortening the post-operative course. (10, 21, 23) 
 
Impact on mortality: 
 
The Cochrane review in 2014 including data from Day and Miller et al found no impact on in 
hospital mortality with the post-operative use of iNO in patients with congenital cardiac 
disease. Long term mortality was not commented on in any of the studies. (3) Most other 
studies either allowed crossover or did not comment on mortality.  
  




The Cochrane review in 2014 found no decrease in mean pulmonary artery pressure (MPAP) 
following treatment with iNO combining data from Day and Morris. They also found an 
increase in methaemoglobin levels, but these did not reach toxic levels. They found no 
significant differences in subgroups comparing iNO to placebo or conventional management. 
(3)  
 
It has been shown that patients with higher pulmonary vascular resistance (PVR) and lower 
partial pressure of oxygen (PaO2) generally respond better to iNO. It was also shown that 
patients with Down Syndrome, with an age of less than 1 year and pre-operative pulmonary 
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hypertension are more likely to require post-operative iNO in a large retrospective review of 
457 patients by Laitenen et al 2000. (24) 
 
Miller et al found a decrease in time to eligibility for extubation in patients treated with iNO. 
(6) 
 
Day et al showed no difference in PaO2: fraction of inspired oxygen (FiO2) between 
treatment and control group. Day, Morris and Russel showed no statistical difference in mean 
arterial pressure and heart rate between treatment and control groups and also that patients 
with higher pulmonary pressures respond better to treatment. (3)  
 
Russel et al 1998 published a randomised double blinded study including 40 patients with 
pre-operative PHT. MPAP was assessed post-surgery. Patients with PHT post operatively 
responded to treatment with iNO with a decrease in MPAP, whilst MPAP in patients with 
only pre-operative PHT and normal post-operative MPAP was unaffected. (25) 
 
A small RCT by Morris et al 2000 including 12 patients looked at the use of iNO in patients 
with confirmed PHT post-operatively. Patients were randomized to receive either iNO or 
hyperventilation to a pH of 7.5 for 30 minutes followed by a washout period of 30minutes 
and then a combination of both treatment modalities for a further 30 minutes. They found a 
selective decrease in PAP and pulmonary vascular resistance index (PVRI) with the use of 
iNO but an additive increase in systemic vascular resistance index (SVRI) and decrease in 




In patients with ARDS, iNO is shown to improve oxygenation only over a short period of 
time that does not extend beyond 24hours. Most studies however date back as far as 15 years, 
and there has since been a change to more lung protective ventilation strategies. Dosing 
regimens also differed between trials and it is not known if a sustained response was lacking 
due to tolerance associated with fixed dosing regimens. In addition, adjunctive maneuvers 
such as prone positioning, the use of neuromuscular blockade and HFOV were not always 
stratified for.  
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There has also been no demonstrated benefit in terms of mortality. Evidence however is poor 
and based on only a few trials in paediatrics. There is some evidence to show that early 
introduction of iNO following diagnosis of ARDS might result in a more sustained 
improvement in oxygenation however this has not been shown to translate to an improvement 
in mortality. There has been no evidence to show that subgroups of patients with different 
underlying pathology respond preferentially to treatment.  
Most early trials have shown an increase in ventilator free, ECMO free and HFOV free days 
in patients treated with iNO, however a large retrospective trial published in 2016 was the 
first to show worsened outcomes in terms of morbidity and cost incurred due to prolonged 
treatment, ventilation and admission. 
 
In patients with PHT following cardiac surgery, a Cochrane review showed no impact on 
mortality, MPAP, MAP, number of PHTCs and PaO2: FiO2. Notwithstanding, the American 
Heart Association and the European Consensus Guidelines suggest early use of iNO for its 
possible effect in decreasing the number of PHTCs and decreasing PVR. These guidelines are 
however established in resource rich settings. This likely indicates that whilst iNO may 
decrease PAP, there are other factors that contribute to mortality such as the right ventricle’s 
ability to deal effectively with the increase in afterload caused by a raised PAP. In a resource 
poor setting there is a lack of evidence to support routine use of iNO in the post operative 
period. 
 
Aims and Objectives of the Research Project: 
 
The aim of this research project is to evaluate the use and outcomes of patients treated with 
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MANUSCRIPT IN PUBLICATION READY FORMAT: 
 
A Review of the Use of Inhaled Nitric Oxide in the PICU at Red Cross Children’s 





Inhaled Nitric Oxide (iNO) functions as a selective pulmonary vasodilator. It is an expensive 
treatment that is often employed as rescue therapy for refractory hypoxaemia in acute 




To describe the response to treatment with iNO. Secondary observations were deaths, co-




A retrospective descriptive study of all patients treated with iNO in the Paediatric Intensive 




A total of 140 patients were treated with iNO during this time period, 82 were for PHT 
following cardiac surgery, 53 for ARDS and 5 for PPHN. A response to treatment was 
observed in 64% of the cohort as a whole, 80% of those with PPHN, 67% of those with PHT 
post-cardiac surgery, and 64% of those with ARDS. A longer duration of ICU and hospital 
admission, and higher in hospital mortality (53%) was seen in the group with ARDS, in 
particular those with adenoviral infection (63%), when compared to patients treated for PHT 
(18%) and for PPHN (20%).  
There is no protocol in place guiding the use of iNO in our unit, and it was found that 
response to treatment was not being objectively measured and documented and that practise 




Considering the cost of treatment and lack of evidence to support beneficial effects of iNO 
therapy, its continued use in our resource poor setting should be guided by protocol.  
 




Nitric oxide (NO) has many features of an ideal pulmonary vasodilator. When inhaled, it has 
a rapid onset of action, is delivered directly to the lungs thereby minimizing systemic side 
effects, and improves ventilation-perfusion mismatch.[1]  
It was first approved by the Food and Drug Administration (FDA) in 1999 for use in neonates 
with persistent pulmonary hypertension of the newborn (PPHN). Since then, there has been 
considerable interest in its potential role as a pulmonary vasodilator in other conditions, and it 
has been employed in severe, refractory hypoxaemia secondary to acute respiratory distress 
syndrome (ARDS) and in pulmonary hypertension (PHT) following cardiac surgery. [2]  It is 
an expensive treatment, and whether or not it improves outcomes, remains controversial.  
 
In patients with ARDS, inhaled nitric oxide (iNO) has been shown to only transiently 
improve oxygenation,[ 3-9] and no improvement in survival has been demonstrated.[1, 3, 4, 8-10] 
Most studies date back as far as 15 years and very few randomized controlled trials (RCTs) 
have been conducted in children.  
In patients with PHT following cardiac surgery, an improvement in mortality following 
treatment with iNO has not been shown.[11, 12] Although some small studies have shown a 
decrease in the number of Pulmonary Hypertensive Crises (PHTCs) post-operatively,[12] 
pooled data shows otherwise. [11, 13] There has also been no significant impact on mean 
pulmonary artery pressure (MPAP), mean arterial pressure (MAP),[11] and oxygenation 
demonstrated.[11, 13] The American Heart Association and the European Consensus Guidelines 
suggest early use of iNO for its possible effect in decreasing the number of PHTCs and 
decreasing pulmonary vascular resistance (PVR).[9, 14, 15] These guidelines were, however, 




Data published in resource limited settings such as ours is lacking. It is also not known 
whether there are subgroups of patients with different underlying diseases or co-morbidities 
that respond differently to treatment.  
In our setting, there are no protocols in place guiding its use and the indications for use, 
dosage, weaning and discontinuation are usually left to the discretion of the attending 
physician. 
 
Due to the paucity of evidence showing improved outcomes with the use of iNO and the 
difference in context between our setting and that of most of the published data, we aimed to 
review its use and the outcomes of patients treated at a tertiary paediatric hospital in the 




A retrospective, descriptive study was performed reviewing all patients treated with iNO in 
the PICU at Red Cross War Memorial Children’s Hospital (RCWMCH) from 2011 - 2015.  
The 22 bed multi-disciplinary PICU admits approximately 1300 patients annually, including 
acute medical admissions, trauma patients and post-surgical patients. Approximately 60% of 
admissions are acute medical admissions and approximately 320 children are admitted 
electively post-cardiac surgery each year. 
Approval was obtained from the RCWMCH Departmental Research Committee (Appendix 
C), as well as the Human Research Ethics Committee of the University of Cape Town 
(HREC Ref: 369/2016, Appendix B).  
Patients that received treatment with iNO during the period being reviewed were identified 
using the electronic PICU database. All patients were included. 
Data pertaining to response to treatment, duration of admission to ICU, underlying diagnoses, 
comorbidities and patient characteristics were extracted from the ICU electronic database and 
patient files. The duration of hospital admission and survival to discharge was obtained from 
the Clinicom database. Results of tests for retroviral disease, blood cultures and respiratory 
tract specimens were accessed via the National Health Laboratory System (NHLS). The 
presence of pulmonary hypertension was ascertained from the electronic database in the ICU 
as well as the department of cardiology’s electronic database of echocardiograms.  
Data relating to costs of using the treatment was obtained from the Pharmacy at RCWMH.  
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Data were entered into a standardized data collection sheet and transferred into a Microsoft 
Excel Spreadsheet. Names and folder numbers were removed to maintain confidentiality. 
Missing data were included and marked as unknown. Medians, proportions and interquartile 
ranges were determined using Stata 12.0 for Mac.  
The number of patients that responded to treatment in the cohort as a whole as well as in 
subgroups with different underlying conditions was assessed as a primary outcome. A 
positive response to treatment was defined as any subjective improvement observed by the 
attending clinician. 
Secondarily we looked at mortality, length of treatment, length of admission as well as co-





A total of 140 patients received treatment with iNO from 2011 to 2015 at Red Cross War 
Memorial Children’s Hospital. The demographics of these patients are shown in table 1.  
  
Table 1. Patient Demographics 
Categorical data are presented as n (%) and continuous data as median(IQR). 
*Gestational age <37weeks at birth 
**Weight for age <-2 Z score on WHO growth chart 
 
The reason for initiating iNO and response to treatment is shown in Figure 1.  
The number of deaths in PICU compared with those at any point during hospital admission is 
shown in Table 2. 
 
Males 72/140  (51) 
Females 68/140  (49) 
Age(months) 3           (1 - 9) 
Weight(kilograms) 4.5        (3.2 - 8.2) 
Premature at birth* 23/140  (16) 
Underweight for age** 72/140  (51) 
Pulmonary TB 4/140    (3) 
HIV positive 5/140    (4) 
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Reasons for Treatment 
Figure 1. Reasons for Initiating Treatment with iNO 
 
 
Of the cohort, 56% (n=78/140) received treatment with iNO as rescue therapy, either during 
an acute pulmonary hypertensive crisis following cardiac surgery or for refractory 
hypoxaemia thought to be due to related to raised pulmonary pressures in ARDS. Three 
percent (n=4/140) were treated prophylactically to prevent pulmonary hypertensive crises 
following cardiac surgery. The reason for initiation of treatment was not documented in 58 
patients.  
All patients that were treated for ARDS had either a positive blood culture, sputum culture or 
viral study on sputum. Of the children treated for ARDS, 8% (n=4/53) of these were admitted 
to the ICU for burns, 9% had abdominal surgery (n=5/53), and 47% had comorbid cardiac 
disease (n=25/53). 




Table 2. Deaths in ICU and Deaths in Hospital 
*Weight for age <-2 z score on WHO growth chart 
**Weight for age >-2 z score on WHO growth chart 
 
The median PIM2 score was 0.09876 (IQR 0.0338 - 0.2827) in the cohort as a whole. In the 
group treated for ARDS, the median PIM2 score was 0.15966 (IQR 0.0269 – 0.3697) 0.2983 
(IQR 0.25012 – 0.8993) in those treated for PPHN and 0.0796 (IQR 0.0336 – 0.2183) in 
those treated for PHT following cardiac surgery.  
 
The duration of treatment with iNO and length of PICU and hospital stay is shown in Table 
3.  





 Deaths in ICU n(%) Deaths in Hospital n(%) 
Entire Cohort 36/140  (26) 44/140   (31) 
PHT Post Cardiac Surgery 9/82      (11) 15/82     (18) 
ARDS 26/53    (49) 28/53     (53) 
PPHN 1/5        (20) 1/5         (20) 
Rescue 29/115  (25) 34/115   (30) 
Prophylaxis 0/8        (0) 2/8         (25) 
WFA<-2* 19/72    (26) 25/72     (35) 
WFA>-2** 16/63    (25)  18/63     (29) 
HIV+ 3/5        (60)   3/5        (60) 
HIV- 33/134  (25) 41/134   (31) 
Premature at Birth 8/23      (35) 9/23       (39) 
Sepsis 24/101  (24) 31/101   (31) 
TB 0/4        (0) 0/4         (0) 
Adenovirus 11/19    (58) 12/19     (63) 
Responders 22/93    (24) 26/93     (28) 
Non-responders 5/20      (25) 6/20       (30) 
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Table 3. Length of Treatment and Duration of Admission 




ICU days Hospital Days 
 Medi n(IQR) Median(IQR) Median(IQR) 
Cohort 3     (2 - 4) 15     (9 - 23) 29      (19 - 50) 
PHT Post Cardiac Surgery 3     (2 - 4) 16     (9 - 22) 30      (20 - 51) 
ARDS 3     (2 – 4) 13     (9 - 23) 28   (16 - 44) 
Adenovirus 3     (2 - 6) 20     (11 - 26) 30      (21 - 52) 
Adenovirus:Survivors 4     (2 - 6) 23     (20.5 - 28.5) 48      (29 - 60.5) 
Adenovirus:Non-Survivors 3     (2 - 3) 11.5  (7 - 25.5) 25.5   (12 - 47) 
PPHN 3.5  (2.3 - 4.8) 23     (6 - 50.5) 38      (13 - 61) 
Underweight for age 3     (2 - 4) 16     (9 - 24.5) 33      (20 - 56.5) 
HIV+ 5     (2,7 - 5) 12     (4 - 17) 24      (13 - 33.5) 
Premature at Birth 3     (2,3 – 3.75) 18     (10 - 26) 34      (18 - 52) 
TB 4.5  (2 - 9) 23     (14.5 - 36.5) 38.5   (29 – 49.5) 
Sepsis 3     (2 - 5) 18     (11 - 25) 32      (22 - 52) 
 
Cost Per Annum: 
Table 4. Annual Expenditure on iNO in South African Rands 
Year Cost 
2011 R345 563 
2012 R229 824 
2013 R178 558 
2014 R352 676 
2015 R334 755 




Our cohort compromised a young population with a median age of 3 months.  
A positive response to treatment was seen in 64% of our cohort, and was similar in those 
treated for ARDS and those for PHT following cardiac surgery. This is similar to findings by 
Medjo[8] and Day[5] who reported positive responses in 69% and 58% of patients treated for 
ARDS respectively. Fioretto[16] reported a 94% response to treatment in patients with ARDS. 
This was however a small trial that likely may pre-dated the change to lung protective 
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ventilatory strategies. Our findings were limited as a standard definition of response to 
treatment was not used and a positive response was defined as any subjective improvement 
observed by the attending clinician. 
  
We found that patients with sepsis and those with adenoviral disease demonstrated better 
responses to treatment than the rest of the cohort. The PIM 2 score in patients with adenoviral 
disease was higher than the rest of the cohort pointing to more severe disease in these 
patients. Dobyns[6] similarly reported that patients with more severe lung disease, those with 
a high OI on starting treatment, and those that are immunocompromised respond better to 
treatment. This may be related to the the role of iNO in modulating inflammation. iNO is 
used universally in our unit as rescue therapy in patients with ARDS that are failing treatment 
with ventilation alone. There is however some evidence to show that early initiation of 
treatment, irrespective of disease severity, improves outcomes.[16]  
The literature shows that iNO effects only a transient improvement in oxygen saturation.[3-9]  
The rationale behind continued use, is that this temporary improvement in oxygenation may 
afford time for other therapies to be instituted or time for recovery of the underlying 
condition itself. Mortality however has not been shown to decrease with treatment with iNO. 
This is likely because these patients often have multi-organ dysfunction that is not improved 
by iNO, and because a response to treatment with improved oxygenation does not necessarily 
indicate an improvement in lung parenchymal disease. 
In patients post-cardiac surgery, iNO therapy is employed on the premise PHTCs are the 
result of an increase in pulmonary vascular resistance and that reversing this would 
ameliorate the crisis. The lack of significant benefit with treatment however suggests that 
there are multiple factors contributing to the development of PHTCs, such as the ability of 
the right ventricle to handle an increase in PVR rather than the absolute increase in PVR 
itself. 
 
Thirty-one percent of the the cohort demised in hospital. This value is higher than predicted 
by the Median Pim2 score (0.09876). Mortality in the ARDS group was 53%. This is higher 
than the reported mortality by Medjo,[8] Day[5], Dobyns[6] and Dowell[17] of 44%, 46%, 43% 
and 34%respectively. Mortality was 63% in those with adenoviral disease, despite the good 
response to treatment seen in this group. We found no difference in mortality in responders 




The cost of treating the cohort with iNO was R1 441 376 during the period being reviewed, 
which is a considerable strain on a resource limited setting. Gupta[10] was the first to show 
worse outcomes in terms of costs and morbidity in patients treated with iNO. We also report 
longer lengths of admission in patients with ARDS and those with TB. When the group with 
adenoviral infection is divided into those that survived to discharge and those that did not, we 
see markedly longer lengths of admission in the survivors, compounding the costs incurred in 
treating these patients.  
 
It is difficult to draw any other conclusions from this study due to its limitations. It was a 
retrospective review without a control group, and many patient’s files and data fields were 
missing. What we did find was that practice was not standardized in our unit due to a lack of 
protocols guiding the indications for use, dosage, weaning and discontinuation of treatment. 
Echocardiography, which is the standard non-invasive investigation of choice in diagnosing 
PHT recommended by the AHA and European Consensus Guidelines,[ 9, 14, 15] was not 
routinely used in our setting. The electronic cardiology database was accessed in an attempt 
to gather data on pulmonary pressures before and after treatment. This was abandoned to 
missing data in most patients.  
A positive response to treatment was judged by the attending clinician and was usually based 
on an increase in oxygen saturation alone. There was no defined increment in saturation that 
was used to denote a response. Oxygenation indices were not calculated in any of the patients 
that were treated, and it was not possible to calculate these retrospectively due to missing 
patient records. Most studies defined a positive response as improvement in the oxygenation 
index (OI) of 20 percent from baseline[17] or an improvement in the ration of PaO2/FiO2 of 
more than 10[8,16]. Response to treatment as judged by an increase in oxygen saturation alone 
may have been confounded by adjunctive measures or therapies such as prone positioning, 
HFOV, neuromuscular blockade or changes in ventilator settings. Response to treatment, or 
lack thereof, was not well documented in patient files. In patients with PHT following cardiac 
surgery, iNO is often used in our unit as rescue therapy in patients with PHTCs. In all of the 
published literature, INO is used prophylactically in an attempt to prevent the onset of 
PHTCs.[12, 13, 18] We did not have access to data regarding the number of PHTCs in our 
cohort. Sildenafil is recommended for use when weaning treatment with iNO.[15] Only 47% 







We report that 64% of patients treated with iNO responded to treatment. Response to 
treatment was however poorly defined and not well documented in the clinical records. The 
use of iNO in the PICU was not standardized and the cost of treatment was high.  
Despite this response to treatment with iNO, mortality in our cohort remained high, 
particularly in those with ARDS and adenoviral infection. Length of hospital and PICU 
admission were also longer in these patients. Further studies in patients with ARDS that 
stratify for underlying conditions are required. Further studies looking at long term outcomes 
and cost effectiveness in resource limited settings are also required to justify ongoing use of 
this expensive treatment. 
In patients with PHT following cardiac surgery, the use of rescue vs prophylactic use needs 
to be further elucidated by good quality RCTs. It is also not clear whether the type of 
underlying cardiac condition is a predictor of response to iNO. 
Overall, practice was not standardized in our unit and the cost of using this treatment is high.  
  
The continued use of this treatment should be protocol driven, with clear criteria for 
indications for use, dosage and weaning, discontinuation, and determining a response to iNO. 
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APPENDIX A: APPROVED STUDY PROTOCOL 
A Review of the use of Inhaled Nitric Oxide in the PICU at Red Cross Children's Hospital  
 
Investigator: Sandhia Padayachee  
 




Inhaled nitric oxide(iNO) has been approved by the Food and Drug Administration in the United 
States for the treatment of persistent pulmonary hypertension of the newborn(PPHN) in term/near 
term neonates since 1990. All other uses are considered off label and evidence to support its use in 
other settings is lacking(1).  
 
Nitric oxide (NO) is primarily a modulator of vascular tone. It is synthesized from the terminal 
nitrogen of L-arginine by the enzyme nitric oxide synthase(NOS). There are three NOS isoforms that 
are expressed in the lung. NO activates guanyl cyclase, leading to the production of cyclic GMP 
which is a vascular smooth muscle relaxant (2). After inhalation, NO diffuses into the bloodstream 
and rapidly reacts with oxyhemoglobin to form methemoglobin and nitrate, and with 
deoxyhemoglobin to form iron-nitrosyl-haemoglobin(3). Inhaled NO(iNO) has many features of an 
ideal pulmonary vasodilator. It has a rapid onset of action, is delivered directly to the lungs thereby 
minimizing systemic effects, and also improves ventilation–perfusion mismatch since areas of the 
lung that are preferentially ventilated will receive more NO(2). It is also known to reduce right-to-left 
intra-cardiac shunting of blood through the foramen ovale and ductus arteriosus(4). Nitric oxide 
affects immune function by modifying the release of cytokines from alveolar macrophages, and 
causing inhibition of active adhesion molecules and the neutrophil oxidative burst involved in 
neutrophil migration. Attenuation of the inflammatory response, particularly in sepsis-induced lung 
injury, may therefore be an important factor in the success or failure of treatment with iNO(5). 
Inhaled nitric oxide has been demonstrated to exert platelet inhibitory effects resulting in prolonged 
bleeding time at both high and low doses. This has however been inconsistently reported in clinical 
trials(5). 
 
Inhalation of low levels of NO appears to be safe. The major clinical toxic effects are due to the 
formation of Nitric Dioxide causing pulmonary edema and methemoglobinemia causing hypoxia, 
however this is only demonstrated at high doses >80ppm(3,4). It is recommended that serum 
methemoglobin be measured at approximately 8 hours and 24 hours after initiation of therapy, and 
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daily thereafter, and that INO should be weaned or discontinued if the methemoglobin level rises 
above 5%(4). INO-mediated lung injury results primarily from inactivation of surfactant protein A 
and decreased surfactant production. Prolonged INO exposure is also associated with a transient 
increase in markers of oxidative lung injury(4).  
 
There is no standardized guideline for the dosage and weaning iNO. In the Neonatal Intensive Care 
Unit(NICU), a significant improvement in the ratio of pulmonary to systemic artery pressure is only 
seen when the iNO dose is at least 20 ppm. When iNO is stopped abruptly, rebound pulmonary 
hypertension sometimes develops. This can usually be overcome by slowly weaning iNO to 1ppm 
before discontinuation(2), increasing FiO2 by up to 20%(4), or the concomitant use of 
phosphodiesterase inhibitors(4). Sildenafil is recommended by the American Heart Association to 
prevent rebound pulmonary hypertension(PH) in patients who have evidence of a sustained increase 
in Pulmonary Artery Pressure(PAP) on withdrawal of iNO or require retreatment with iNO despite 
gradually weaning the dose(6). This rebound phenomenon is not seen when treatment with iNOis 
limited to 30 min. This supports prompt discontinuation of INO following a short trial in patients that 
don't respond(4).  
 
The main use of iNO in the Paediatric Intensive Care Unit (PICU) at Red Cross War Memorial 
Children’s Hospital (RCWMCH) has been for the management of pulmonary hypertension post 
cardiac surgery. A Cochrane review showed no difference in mortality, number of pulmonary 
hypertensive crises(PHC), changes in mean pulmonary artery pressure, mean arterial pressure or 
oxygenation with the use of iNO vs placebo or conventional management of pulmonary hypertensive 
crises. Conventional management includes hyperventilation, use of sodium bicarbonate, inotropic and 
vasodilatory agents, intravenous sedatives and neuromuscular blockade. A significant increase in the 
methaemoglobin level in patients treated with iNO was demonstrated, although they did not reach 
toxic levels(7). There are, however, trials that have shown lowered pulmonary vascular resistance, 
lower frequency of pulmonary hypertensive crises and shortened the time to extubation(8), and the 
American Heart Association recommends that in addition to conventional postoperative care, iNO 
should be used as the initial therapy for PHCs and right-sided heart failure(9). Although the frequency 
of PHC was reduced by the use of inhaled nitric oxide, they were not completely abolished. This 
implies that other pathogenic mechanisms in addition to a relative deficiency of nitric oxide are 
involved in postoperative pulmonary hypertension(8).  
 
In our resource limited setting where extra corporeal membrane oxygenation(ECMO) is not available, 
rescue therapy with iNO is often employed as a last resort in children with refractory hypoxaemia 
from acute respiratory distress syndrome (ARDS). iNO is associated with a transient improvement in 
oxygenation in the first 72hours in older children and adults with ARDS, but there is no significant 
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effect on mortality(10,5,9). This is thought to be due to the fact that most patients dying from ARDS 
suffer from multiple organ system failure, therefore lung-selective therapy may not improve the 
overall survival rate(11). Limited data demonstrates a decrease in the duration of ventilation, length of 
stay in the intensive care unit and length of stay in hospital(10). 
Although the evidence shows no benefit on mortality, most studies did not stratify for primary disease 
or take into account combined treatment modalities such as prone positioning or high Positive end 
expiratory pressure or low tidal volume protective lung ventilation(10).  
 
iNO appears to increase the risk of renal impairment among adults but not the risk of bleeding or 
methaemoglobin or NO2 formation(10). A meta-analysis actually demonstrated a trend towards 
increased mortality in patients receiving nitric oxide(9). Possible reasons for non response to 
treatment are the prolonged fixed dosing regimens that were used in most trials may have attenuated 
benefit over time because of increased sensitisation, dampening the oxygenation benefit while 
continuing to expose patients to oxidative damage, or confounding by concurrent use of a harmful 
mechanical ventilation strategy(9). Although there has been a consistent lack of a mortality benefit 
across trials, the possibility of some subgroups of patients benefiting from nitric oxide has not been 
studied sufficiently. In an adult study, significant and sustained improvement in oxygenation in 
patients with ARDS due to H1N1 virus infection was demonstrated as opposed to the transient 
response that is usually seen(12). This raises the possibility that specific pulmonary infections, 
opposed to extra pulmonary causes of ARDS, behave differently in response to iNO. The use of nitric 
oxide as rescue therapy for patients with critically low oxygenation is also not well researched, and 
the short term improved oxygenation achieved may create a window for other strategies to improve 
lung function, such as treatment of the underlying cause of ARDS(9). 
 
In term/near term infants with PPHN, response to iNO is not shown to be superior to that of high 
frequency oscillatory ventilation(HFOV) alone(13). If used it is recommended that INO therapy be 
instituted early in the disease course(4). Although iNO reduces the need for ECMO and improves 
oxygenation, mortality rates are not decreased. Echocardiographic evidence of PPHN is not shown to 
affect outcome. The incidence of disability and deafness is similar between tested survivors who 
received nitric oxide or not(1)and lung function during early infancy was not adversely affected(4).  
Sildenafil is a reasonable adjunctive therapy for infants with PPHN who are refractory to iNO, 
especially with an oxygenation index that exceeds 25(6).  
 
In very ill preterm infants, although authors of a cochrane review concluded that iNO as rescue 
therapy does not appear to be effective(14) AHA guidelines support its use in severe hypoxemia that 
is due primarily to PPHN physiology rather than parenchymal lung disease, particularly if associated 
with prolonged rupture of membranes and oligohydramnios, as well as  in infants with established 
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BPD and symptomatic PH(6). The outcome of infants with congenital diaphragmatic hernia(CDH) is 
not improved, possibly due to left ventricular dysfunction complicating CDH(6). 
Aims: 
 
To review the PICU use of nitric oxide at RCWMCH to better understand its effect on patient 





1. To document the response of patients treated with iNO. 
Secondary: 
1.  To describe the indications for starting treatment with iNo in the PICU.  
2. To describe clinical characteristics of patients that responded to iNO. 
3. To determine whether certain patient characteristics are associated with a response to iNo. 
4.   To describe the PICU and hospital mortality rates of children treated with iNo.  





This is a retrospective cohort study reviewing all patients treated with nitric oxide in the PICU from 
2011-2015. Data will be extracted retrospectively from patient files as well as the PICU database. All 
data will be captured using the data sheet attached and entered into an electronic database. After all 
required data has been captured, names and folder numbers will be removed and patients will be 
assigned random numbers to maintain confidentiality. This will then be submitted to a statistician for 
analysis. 




This study is set in the PICU at RCWMCH. The 22 bed multi-disciplinary PICU admits 
approximately 1300 patients annually. Approximately 60% of admissions are acute medical and 







We estimate that 40 patients per annum are treated with iNO at RCWMCH, which translates to 
approximately 200 patients over the 5year period studied. This includes patients post cardiac surgery, 
those with confirmed pulmonary hypertension, diaphragmatic hernias, and acute respiratory 
infections. Very few newborns with PPHN are treated at RXH PICU as they are managed 
predominantly at specialized neonatal units.  
All patients that were treated with iNO from 2011-2015 will be included in the study with no 
exclusions.  
 
Data Analysis:  
 
Findings will be presented using tables, graphs and descriptive statistics (as appropriate). 
Nominal categorical data will be generated for the primary outcome investigated. The data will be 
described as proportions and percentages. The hypothesis will be tested using contingency tables and 
either the Chi squared test for association or the Fisher Exact test. We will use the cochrane rule to 
decide which test to use. We will use the same analysis to test for associations between patient 
characteristics and outcomes.   
Numerical data will be generated for no of days treated, highest dose of treatment used, no of days in 
ICU, PIM2 score on admission and oxygenation index before treatment. These will be described as 
means with standard deviations or medians with interquartile ranges if the data is skewed.  
Trends in the number of patients treated over the 5 year period will be presented using raw data on a 
histogram. 
A significance value of P<0.05 will be used for all analysis. Population estimates will be described 
using 95% confidence intervals. 
Data analysis will be performed using Stata/IC(Statacorp) for Windows, version 12.1. 
A statistician will be consulted to verify all calculations.  
 
Dissemination of information: 
 
The results of this study will be written up and reported in the form of a research report that meets the 
requirements of the MMed (Paediatrics) degree program. 
Data will be presented to the Department of Paediatrics and submitted for publication in a peer 








Risks to study participants: 
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As this is a retrospective study, consent from each individual parent will not be sought. Ethical 
approval from the Human Research Ethics Committee of the University of Cape Town and 
RCWMCH Research Committee will be obtained prior to beginning the research project. The study 
will be developed and carried out in accordance with the Declaration of Helsinki, 2013. 
Beneficence:  Although the study does not directly benefit the patients being studied, we aim to 
improve patient care in the future by reviewing current practice. 
Non-maleficence:  No individual will be harmed as a result of this study.   
Autonomy and consent: As this is a retrospective trial, consent from each individual parent will not be 
sought.  
Confidentiality: Patient confidentiality will be strictly maintained. Identifying details of patients will 
be omitted once data capturing is completed by the investigator. 
Actions related to gross abnormalities:  If any gross adverse outcomes become evident during the 
study, clinical specialists will be consulted.  
 
Strengths and limitations: 
 
This study is limited in that it is a retrospective review and all required data may not have been 
adequately recorded . Furthermore there isn't a control population for comparison. It will however 
give a reasonable overview of outcomes achieved and possible predictors of outcomes to guide future 




All data will be captured electronically and no costs will be involved. The cost of recruiting a 
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APPENDIX E: AUTHOR GUIDELINES: SOUTH AFRICAN JOURNAL 
OF CRITICAL CARE 
 
   
General article format/layout 
General: 
• Manuscripts must be written in UK English (this includes spelling). 
• The manuscript must be in Microsoft Word or RTF document format. Text must be 
1.5 line spaced, in 12-point Times New Roman font, and contain no unnecessary 
formatting (such as text in boxes). Pages and lines should be numbered consecutively. 
• Please make your article concise, even if it is below the word limit. 
• Qualifications, full affiliation (department, school/faculty, institution, city, country) 
and contact details of ALL authors must be provided in the manuscript and in the 
online submission process. 
• Abbreviations should be spelt out when first used and thereafter used consistently, 
e.g. 'intravenous (IV)' or 'Department of Health (DoH)'. 
• Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
• Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
• Round brackets (parentheses) should be used, as opposed to square brackets, which 
are reserved for denoting concentrations or insertions in direct quotes. 
• Medical drugs should be referred to by their generic name although the trade name 
may be used in brackets in the text once if unique. 
Research 
Guideline word limit: 3 000 words (excluding abstract and bibliography) 
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
title of the manuscript should concisely describe the study but should not include the 
outcome. The introduction should be concise – no more than three paragraphs – on the 
background to the research question, and must include references to other relevant published 
studies that clearly lay out the rationale for conducting the study. Some common reasons for 
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conducting a study are: to fill a gap in the literature, a logical extension of previous work, or 
to answer an important question. If other papers related to the same study have been 
published previously, please make sure to refer to them specifically. At the end of the 
introduction clearly state the aim or objective of the study. The primary and secondary 
outcomes should be specified. 
In the Methods section describe in sufficient detail so that others would be able to replicate 
the study should they need to. Sections of the methods that have been described in previous 
publications need only be referenced. The statistical methods should be described. Where 
appropriate, sample size calculations should be included to demonstrate that the study is not 
underpowered. 
Results should describe the study sample as well as the findings from the study itself, but all 
interpretation of findings must be kept in the discussion section. The conclusion should 
briefly summarise the main message of the paper and provide recommendations for further 
study. 
The discussion should be confined to an interpretation of your results with respect to your 
stated aim and if applicable, a comparison to the results of similar studies. The strengths and 
weaknesses of your study should be discussed. 
The conclusion should be confined to an interpretation of the results of the study and a 
recommendation if applicable. 
• May include up to 6 illustrations or tables. 
• References should only include the most recent and relevant articles. A maximum of 
30 references is advised.  
Structured abstract  
• This should be no more than 250 words, with the following headings: 
o Background: why the study is being done and how it relates to other 
published work. 
o Objectives: what the study intends to find out 
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o Methods: must include study design, number of participants, description of 
the research tools/instruments, any specific analyses that were done on the 
data. 
o Results: first sentence must be brief population and sample description; 
outline the results according to the methods described. Primary outcomes must 
be described first, even if they are not the most significant findings of the 
study. 
o Conclusion: must be supported by the data, and be aligned with the 
conclusion in the main text. 
o Please ensure that the structured abstract is complete, accurate and clear and 
has been approved by all authors. It should be able to be intelligible to the 
reader without referral to the main body of the article. 
o Do not include any references in the abstracts.  
References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be accepted. 
If reference manager software is used, the reference list and citations in text are to be 
unformatted to plain text before submitting. 
	
	
